Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.380
-0.070 (-4.83%)
At close: Mar 5, 2026, 4:00 PM EST
1.340
-0.040 (-2.90%)
Pre-market: Mar 6, 2026, 8:20 AM EST
Fate Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 6.65 | 13.63 | 63.53 | 96.3 | 55.85 | |
| Revenue Growth (YoY) | -51.24% | -78.55% | -34.03% | 72.44% | 77.66% | |
| Cost of Revenue | 91.9 | 118.53 | 157.19 | 320.45 | 215.52 | |
| Gross Profit | -85.25 | -104.9 | -93.65 | -224.15 | -159.67 | |
| Selling, General & Admin | 61.35 | 90.64 | 96.86 | 84.23 | 57.32 | |
| Operating Expenses | 61.35 | 90.64 | 96.86 | 84.23 | 57.32 | |
| Operating Income | -146.6 | -195.54 | -190.51 | -308.39 | -216.99 | |
| Interest & Investment Income | 11.05 | 17.29 | 17.19 | 5.84 | 1.31 | |
| Other Non Operating Income (Expenses) | 0.34 | 6.73 | 7.3 | 20.32 | 3.53 | |
| EBT Excluding Unusual Items | -135.22 | -171.53 | -166.03 | -282.22 | -212.15 | |
| Merger & Restructuring Charges | -1.1 | - | - | - | - | |
| Asset Writedown | - | -14.74 | - | - | - | |
| Other Unusual Items | - | - | 5.1 | 0.5 | - | |
| Pretax Income | -136.32 | -186.26 | -160.93 | -281.72 | -212.15 | |
| Net Income | -136.32 | -186.26 | -160.93 | -281.72 | -212.15 | |
| Net Income to Common | -136.32 | -186.26 | -160.93 | -281.72 | -212.15 | |
| Shares Outstanding (Basic) | 119 | 114 | 98 | 97 | 95 | |
| Shares Outstanding (Diluted) | 119 | 114 | 98 | 97 | 95 | |
| Shares Change (YoY) | 4.49% | 15.52% | 1.64% | 2.19% | 15.00% | |
| EPS (Basic) | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | |
| EPS (Diluted) | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | |
| Free Cash Flow | -112.04 | -123.6 | -138.42 | -283.77 | -213.57 | |
| Free Cash Flow Per Share | -0.94 | -1.09 | -1.41 | -2.93 | -2.25 | |
| Gross Margin | - | - | -147.41% | -232.77% | -285.92% | |
| Operating Margin | -2205.90% | -1434.52% | -299.86% | -320.24% | -388.56% | |
| Profit Margin | -2051.08% | -1366.46% | -253.30% | -292.55% | -379.89% | |
| Free Cash Flow Margin | -1685.78% | -906.79% | -217.87% | -294.68% | -382.43% | |
| EBITDA | -133.7 | -176.58 | -172.23 | -294.63 | -211.14 | |
| EBITDA Margin | - | - | -271.09% | - | - | |
| D&A For EBITDA | 12.9 | 18.96 | 18.28 | 13.76 | 5.85 | |
| EBIT | -146.6 | -195.54 | -190.51 | -308.39 | -216.99 | |
| EBIT Margin | - | - | -299.86% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.